Trendlines Investments Israel.

Barak Singer has 20 years of experience in management, business development, investment banking, and venture capital, including as VP Business Development of Trendlines Medical from December 2016 until February 2019, when he was appointed CEO of Trendlines Investments Israel.

Prior to joining Trendlines, Barak held several senior management positions, including Managing Director, Co-Head of Investment Banking, and Head of Healthcare at Tamir Fishman & Co., representing the Royal Bank of Canada’s (NYSE: RY) investment banking arm in Israel, RBC Capital Markets. He also served as VP Business Development at Can-Fite BioPharma Ltd. (NYSE: CANF) and CEO of its subsidiary OphthaliX Inc., VP Business Development at Xenia Venture Capital Ltd., and was a Co-Founder and CEO at Or Capital Healthcare Partners.

Barak received his LLB and BA in business (both with distinction) from the Interdisciplinary Center Herzliya, Israel.

Ofir Hazut brings over 15 years of experience and knowledge in investments in life science start-ups and companies. Ofir is a serial entrepreneur in medical device sector and has served as board member and CEO of medical and agritech companies. He has vast experience as an investor after working with VCs on investment strategy, deal flow and due diligence processes. Prior to joining Trendlines, Ofir held the position of Director of Business Development at Evogene (NASDAQ: EVGN) and CEO of MEway Pharma, a medical device company.

Ofir holds an M.Sc degree in neuroscience from Tel Aviv University and an MBA from Bar-Ilan University.

Shahar has extensive technology and management experience including technology assessment, product design and development.

Tamar has over seven years’ experience in scouting and deal flow in the life sciences technology industry at ICL Group, as well as application specialist at GE Healthcare and Bio-Rad Laboratories.

Tamar holds a PhD in chemistry and philosophy from Tel Aviv University and an MBA from the Imperial College London.